Enabling Precision Cancer Clinical Trials: A molecular profiling platform for the Australian clinical trials industry
To facilitate genomics testing and patient matching for clinical trials and focussed therapies the Garvan will engage at least 5 companies and have 250 tests conducted on a purpose built SME engagement platform.
This project will deliver a molecular profiling platform to increase capacity in Australia’s clinical trial sector, and increase the attractiveness of Australia to the international pharmaceutical industry. The platform includes a clinically-accredited molecular test for cancer trials, a genomics data platform to support clinical trials, and patient-matching capabilities to facilitate clinical trial recruitment.
Visit Garvan Institute of Medical Research's website for more information.
Twitter: GarvanInstitute
LinkedIn: Garvan Institute of Medical Research
| Consortium lead | The Garvan Institute of Medical Research |
| Consortium members | NHMRC Clinical Trials Centre, NSW Early phase Clinical Trials Alliance (NECTA), Genome.One, Linear Clinical Research |
| MTPConnect grant | $400,000 |
| Industry contribution | $428,540 |
| Project duration | April 2018 - March 2020 |
| Contact | A/Prof Luke Hesson, The Garvan Institute of Medical Research - l.hesson@garvan.org.au |